GLP-1 receptor agonists are the most consequential drug class to emerge in obesity and type-2 diabetes since metformin. The category started with exenatide and liraglutide, broke commercial ceilings with semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), and is now expanding into orals (orforglipron, oral semaglutide), triple agonists (retatrutide), and amylin combinations (cagrisema, eloralintide).
The signal worth tracking has shifted. Weight loss alone is no longer the headline — secondary indications are. SELECT showed a 20% drop in major adverse cardiovascular events for non-diabetic adults with obesity. A Mass General Brigham analysis in JAMA reported 42–58% lower heart-failure hospitalizations in HFpEF. AAN 2026 added migraine, dementia incidence, and Parkinson's signals to the growing list. The Phase 3 EVOKE Alzheimer's trial, by contrast, missed its endpoint.
Gallup's July 7, 2026 poll release documented the first large-population evidence that GLP-1 uptake is bending the US obesity curve: 11% of US adults now take a GLP-1 for weight loss (up from 3% in 2024 and 8% in 2025), and the US adult obesity rate has drifted from a 2022 peak of 39.9% down to 36.4% in 2026. Awareness climbed from 80% to 91% over the same span. Browse the latest below, or filter by drug at #semaglutide, #tirzepatide, #orforglipron, and #retatrutide.
A Stanford-led retrospective pre-post cohort study presented June 13 at ENDO 2026 in Chicago used NIH All of Us Research Program data linking electronic health records with Fitbit activity in 1,950 adults with obesity who started GLP-1 medications. Among the 753 with sufficient wearable data, mean daily steps dropped from 5,047 before GLP-1 initiation to 4,487 after (-560 steps, p<0.001); moderate-to-vigorous activity fell from 27.9 to 22.2 minutes per day (-5.7 minutes, p<0.001). The largest declines occurred in men and in people with pre-existing joint or muscle pain; age, heart failure, and stroke history did not change the pattern. Lead author Surya Maharjan flagged the activity drop as a concern given GLP-1-associated lean-mass loss.
A research team from University Hospitals Coventry and Warwickshire and Warwick Medical School presented meta-analysis data from randomized controlled trials at ENDO 2026 on June 14 showing that 24 weeks of GLP-1 receptor agonist treatment improved testosterone levels, sperm count, and sperm morphology in men ages 18 to 65 with obesity-related low testosterone. Principal investigator Pratibha Natesh proposed reduced inflammation and metabolic stress as candidate mechanisms, with the GLP-1 class potentially preferable to testosterone replacement therapy in this population because TRT can suppress endogenous sperm production. The findings were drawn from men with high BMI, so external validity to normal-weight populations is unclear.
AJMC reported real-world claims data showing that 51.3% of patients on GLP-1 drugs carry at least one diagnosis tied to an emerging GLP-1 indication, 13.8% carry two, and 6.8% carry three or more. Obstructive sleep apnea led the comorbidity prevalence at 25.5%, followed by major depressive disorder at 18.2%, chronic kidney disease at 10.6%, and NAFLD/NASH at 10.3%. The numbers quantify the indication creep the field has been narrating since ADA: prescribers are increasingly writing GLP-1s for patients whose secondary conditions align with the expanding regulatory map (Wegovy CV, FLOW kidney, SURMOUNT-OSA, ESSENCE MASH).
Novo Nordisk presented Phase 2 data for zenagamtide (formerly amycretin), its unimolecular GLP-1 and amylin receptor agonist, at ADA 2026 in 262 adults with type 2 diabetes randomized across six subcutaneous doses (0.4 to 40 mg) versus placebo. The 40 mg arm cut HbA1c by 1.71 percentage points and reduced body weight by 14.6% at 36 weeks, with nearly 89% of patients reaching HbA1c below 7%. The study met its primary HbA1c endpoint across all doses; Novo plans Phase 3 in H2 2026 and hosted a same-day R&D investor event.
5W Public Relations published the fourth installment of its AI Visibility Index, finding two manufacturers — Novo Nordisk and Eli Lilly — account for nearly 100% of GLP-1-class citations inside ChatGPT, Claude, Perplexity, and Google AI Overviews. Five products — Wegovy, Zepbound, Ozempic, Mounjaro, and Saxenda — capture about 57% of all weight-loss-and-metabolic-health category citations. Founder Ronn Torossian attributes the citation moat to peer-reviewed clinical data cadence, named-author editorial coverage, and regulatory events treated as content events, with content velocity outpacing the broader news cycle.
Prof. John Wilding (University of Liverpool) and colleagues will present at ECO 2026 a real-world observational study tracking obesity-linked complication rates by degree of GLP-1-driven weight loss. In the year following GLP-1 treatment initiation, 27.0% of patients had BMI reductions <5%, 22.4% had 5-<10%, 14.1% had 10-<15%, 15.8% had ≥15%, and 20.8% gained BMI. Over a mean 11-month follow-up, patients with ≥15% BMI reduction had 37% lower osteoarthritis odds, 30% lower CKD odds, 69% lower OSA odds, and 32% lower heart failure odds versus those with 0-5% reduction (all statistically significant except heart failure). Incidence per 1,000 person-years: 21.4 OA, 21.1 CKD, 20.3 OSA, 3.9 HF. The data quantifies the value of pushing for deeper weight loss rather than cruise-control dosing.
A Nature Communications umbrella review by Kong, Zhao, Zhang and colleagues synthesized 123 meta-analyses covering 464 outcomes from 5,617 articles to comprehensively assess GLP-1 receptor agonist effectiveness and adverse events across diverse outcomes. Outcomes were grouped into seven categories: endocrine and metabolic, cardiovascular, cancer, renal, respiratory, mortality and adverse events, and other. The review documented improvements in metabolic, cardiovascular, renal, and respiratory outcomes plus cognitive function, with potential reductions in fracture risk and all-cause mortality in selected populations. Increased risks were observed for diabetic retinopathy, ketoacidosis, gastrointestinal events, and treatment discontinuation — useful evidence-summary input for ECO 2026 in Istanbul (May 12–15) and the prevention-trial proposal that 21 obesity-and-cancer experts will present there.
Ahead of the European Congress on Obesity in Istanbul (May 12–15), a 21-expert global panel of obesity and cancer specialists will present a research proposal for a 10-year prospective trial testing GLP-1 receptor agonists like semaglutide and tirzepatide for prevention of obesity-related cancers. The proposal builds on the SELECT trial's established cardiovascular benefit, real-world dementia-incidence reductions, and the broader case that GLP-1s influence multiple aging-driven disease categories. The Istanbul meeting is the same venue where Novo Nordisk will present 52 abstracts on Wegovy, the higher-dose 7.2 mg formulation, the Wegovy pill, and CagriSema, including data on women's obesity, perimenopause, and migraine.
Novo Nordisk announced May 1 that Rybelsus is being retired as a US brand and the molecule re-launches Monday May 4 as Ozempic Pill at 1.5/4/9 mg in 70,000+ pharmacies. Bloomberg and Fierce Pharma framed it as a marketing-driven move: same active ingredient as Rybelsus, but reformulated for improved absorption and bioavailability so smaller tablets achieve equivalent efficacy. Aligning the oral and injectable products under a single brand is meant to simplify prior authorizations and prescribing discussions, and to capitalize on Ozempic's recognition as Novo defends market share against Lilly's Foundayo. Rybelsus continues outside the US.
DistilINFO and an Endocrine review published May 1 consolidated the clinical literature on accelerated facial aging in patients on GLP-1 receptor agonists. A 2025 Vanderbilt study reported approximately 9% midface volume loss per 10 kg of total weight loss, with GLP-1-mediated lipolysis disproportionately affecting superficial and medial cheek fat pads. The American Academy of Facial Plastic and Reconstructive Surgery reported a 50% increase in face-grafting procedures in the past year tied to the trend, and one in four surgeons expects continued growth in nonsurgical demand (fillers, microneedling, RF, CO2 laser). Mechanistic work in Endocrine adds a possible direct effect on adipose-derived stem cells beyond rapid fat loss alone.
The Partnership for Safe Medicines issued a May statement strongly supporting the FDA's April 30 proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B outsourcing-facility bulks list, citing 'sound science, sound law, and a clear-eyed commitment to patient safety.' The Partnership cited more than 455 adverse-event reports linked to compounded semaglutide and more than 320 tied to compounded tirzepatide — many involving dosing errors from multidose vials, some leading to hospitalization — as the safety basis. The group plans to submit a full comment to the Federal Register docket before the June 29 deadline and is encouraging other patient-safety groups to do the same.
Orrick published a May 2026 client memo walking through the FDA's April 30 proposal to formally exclude semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and liraglutide (Victoza, Saxenda) from the 503B outsourcing-facility bulk drug substances list. The memo flags that the FDA declared the tirzepatide shortage resolved in October 2024 and the semaglutide shortage resolved in February 2025, removing the two legal pathways that previously enabled large-scale compounding. Orrick advises weight-loss clinics, medical spas, and telehealth platforms still relying on compounded GLP-1 products to consult counsel ahead of the June 29 comment deadline.
Novo Nordisk announced May 1 that Ozempic (semaglutide) tablets at 1.5 mg, 4 mg, and 9 mg will be available across 70,000+ U.S. pharmacies starting Monday, May 4, for adults with type 2 diabetes. The product is the only FDA-approved oral peptide GLP-1 medication cleared for both primary and secondary cardiovascular risk reduction in adults with T2D, manufactured end-to-end in the United States. Insured patients can access the pill for as little as $25 for up to a 3-month supply; self-pay patients face $149–$299/month depending on dose strength.
GoodRx announced May 1 that it has added self-pay access for the Ozempic pill, offering eligible patients with type 2 diabetes the medication at $149/month for the 1.5 mg dose, $199/month for 4 mg, and $299/month for 9 mg at participating pharmacies nationwide. The collaboration extends GoodRx's existing work across Novo Nordisk's full semaglutide portfolio, letting cash-paying patients bypass insurance complexity at the counter. The launch closes a transparency gap that has dogged consumer access to oral GLP-1 therapy.
ScienceDaily on April 27 highlighted a University of Utah Department of Chemistry team's discovery — published in ACS Bio & Med Chem Au — that the radical-SAM enzyme PapB can macrocyclize GLP-1-like peptides in one step by forming a thioether bond between a cysteine thiol and the C-terminal carboxylate, even when the C-terminal residue is D-configured, β-amino-acid-derived, or N-methylated. The chemistry compresses what is normally a multi-step late-stage cyclization into a single enzymatic reaction, materially reducing the cost and complexity of producing oral-bioavailable peptide drugs. The work positions PapB as a platform tool for next-generation incretin and macrocyclic peptide programs.
A Nature paper from Liskiewicz, DiMarchi, Tschöp, Müller and colleagues introduces a unimolecular peptide-drug conjugate that combines a GLP-1R/GIPR co-agonist peptide with the pan-PPAR (α/γ/δ) agonist lanifibranor via a pH-sensitive linker. After receptor-mediated internalization, the linker cleaves and lanifibranor escapes to the nucleus to activate PPARs while the peptide moiety drives GLP-1R/GIPR signaling at the membrane. In obese, diabetic mice the conjugate produced greater weight loss and insulin sensitization than equimolar dosing of the unconjugated peptide and lanifibranor, without the typical PPAR-related cardiac and weight-gain safety signals.
WHO's December 2025 first-ever GLP-1 guideline for obesity treatment in adults — published as a JAMA Special Communication and updated through Q1 2026 — continues to influence national and payer policy. WHO issued conditional recommendations for chronic GLP-1 therapy as part of comprehensive obesity management, while flagging cost, long-term safety, health-system preparedness, and equity implications. The framework directly informs the political economy of the U.S. Medicare Bridge program extension to 2027 and similar coverage debates globally.
Novo Nordisk announced April 23 positive topline results from the PIONEER TEENS trial: a 52-week, randomized, double-blind, placebo-controlled Phase 3a study of oral semaglutide (3, 7, or 14 mg once daily) in 132 children and adolescents aged 10-17 with type 2 diabetes. Oral semaglutide reduced HbA1c by 0.83 percentage points more than placebo at 26 weeks with a well-tolerated safety profile. Pending regulatory approvals, it would be the first oral GLP-1 RA for this pediatric population. Novo expects to file for label expansion in the US and EU in H2 2026.